UNC119: A Promising Drug Target for Various Diseases (G9094)

Target Name: UNC119

NCBI ID: G9094

UNC119

UNC119: A Promising Drug Target for Various Diseases

UNC119 (IMD13) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the IMD (inositol-dependent protein kinase) family, which is known for its role in intracellular signaling.

Recent studies have identified UNC119 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its unique structure and the fact that it is expressed in a wide range of tissues, making it a promising target for small molecules that can inhibit its activity.

One of the key features of UNC119 is its catalytic active site, which is located at the N-terminus of the protein. This site is known for its ability to interact with small molecules, such as inhibitors, which can alter the activity of the protein.

In addition to its catalytic active site, UNC119 also has a unique structural feature called a \"T-loop\" region, which is located between its N-terminus and the transmembrane region of the protein. This region is known for its ability to interact with a variety of ligands, including small molecules and proteins.

UNC119 has been shown to play a role in a wide range of cellular processes, including intracellular signaling, cell division, and neurotransmission. Its role in these processes has led to its potential as a drug target for a variety of diseases.

One of the key advantages of targeting UNC119 is its widespread expression in various tissues, which makes it a promising target for small molecules that can inhibit its activity. This is because the disruption of UNC119's function in any one tissue is likely to have a minimal impact on the overall function of the cell.

In addition to its potential as a drug target, UNC119 has also been shown to be a potential biomarker for a variety of diseases. This is because its expression is often reduced in the brains and other damaged tissues of diseases, such as neurodegenerative diseases and cancer. This suggests that its levels may be a useful indicator of the severity or stage of these diseases.

Overall, UNC119 is a protein that has great potential as a drug target for a variety of diseases. Its unique structure and widespread expression in various tissues make it an attractive target for small molecules that can inhibit its activity. Additionally, its potential as a biomarker for diseases makes it an important tool for the development of new treatments.

Protein Name: Unc-119 Lipid Binding Chaperone

Functions: Involved in synaptic functions in photoreceptor cells, the signal transduction in immune cells as a Src family kinase activator, endosome recycling, the uptake of bacteria and endocytosis, protein trafficking in sensory neurons and as lipid-binding chaperone with specificity for a diverse subset of myristoylated proteins. Specifically binds the myristoyl moiety of a subset of N-terminally myristoylated proteins and is required for their localization. Binds myristoylated GNAT1 and is required for G-protein localization and trafficking in sensory neurons. Probably plays a role in trafficking proteins in photoreceptor cells. Plays important roles in mediating Src family kinase signals for the completion of cytokinesis via RAB11A

The "UNC119 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UNC119 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets